Form 4: IRADIMED CORP: Insider Sells Shares Under 10b5-1 Plan

Roger E. Susi, CEO and Director of IRADIMED CORP, reported the sale of common stock totaling 5,648 shares across multiple transactions executed on April 6th and 7th, 2026, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Roger E. Susi, who holds the positions of CEO, President, Chairman, Director, and is a 10% owner of IRADIMED CORP, executed a series of stock sales.
• These transactions occurred on April 6th and April 7th, 2026.
• The sales were conducted under a Rule 10b5-1 trading plan adopted on November 5, 2025, which is designed to comply with affirmative defense conditions for insider trading.
• A total of 5,648 shares were sold across these transactions.
• The weighted average sale prices ranged from $94.36 to $97.00 per share.
• Following these transactions, Susi's beneficial ownership of IRADIMED CORP common stock is detailed, with some shares held indirectly through trusts and a revocable trust.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as neutral to slightly negative due to the sale of shares by a key executive, despite the use of a Rule 10b5-1 plan, which mitigates some concerns.

Positives

• The sales were executed under a Rule 10b5-1 trading plan, indicating a pre-determined and structured approach to selling shares, which can mitigate concerns about opportunistic insider trading.
• The reporting person is providing full information regarding the number of shares and prices upon request, demonstrating transparency.

Negatives

• Significant sale of shares by a key executive (CEO, Chairman, Director) and 10% owner, which could be interpreted negatively by the market.
• The total number of shares sold across the reported transactions is 5,648.

Risks

• Potential for negative market perception due to insider selling, even if conducted under a 10b5-1 plan.
• The filing does not provide specific reasons for the sales, leaving room for speculation.

Future Outlook

The filing itself does not contain forward-looking statements or guidance. The transactions were executed under a pre-existing trading plan.

Management Comments

• The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2025.
• The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Industry Context

StockSavvy.ai notes that insider sales, particularly by C-suite executives and significant shareholders, are common events reported via Form 4. The use of a Rule 10b5-1 plan is a standard mechanism for insiders to diversify their holdings or raise liquidity in a manner that is compliant with securities regulations, aiming to avoid the appearance of trading on material non-public information.

Stakeholder Impact

• Shareholders may view the sale by a key executive with caution, potentially impacting short-term stock sentiment.
• Employees may also be influenced by insider selling activity.
• Creditors and suppliers are unlikely to be directly impacted by this specific transaction.

Next Steps

• The reporting person may continue to execute trades under the existing Rule 10b5-1 plan.
• The issuer or a security holder may request further information regarding the transactions.

Key Dates

Recommendation

The filing reports routine stock sales by a key executive under a pre-established 10b5-1 plan. While insider selling can be a negative signal, the structured nature of the sale under a compliant plan suggests it is not necessarily indicative of a lack of confidence in the company's future prospects. Without additional context on the company's financial performance or strategic outlook, a 'hold' recommendation is prudent, advising investors to monitor future filings and company performance.

Keywords

IRADIMED CORP, IRMD, Form 4, Insider Trading, Stock Sale, Rule 10b5-1, Beneficial Ownership, Roger E. Susi, CEO, Director, 10% Owner